Recursion Pharmaceuticals

Recursion said its AI-driven platform has evolved from a pure discovery platform into an integrated biotech company with multiple first-in-class programs. Management highlighted sustained cost reductions of about 40% after the Exscientia integration, strong early phase‑2 data for REC-4881 in familial adenomatous polyposis, and more than $525 million in upfronts and milestones from partnerships with Roche/Genentech and Sanofi. The company stressed the unreplicability of its data factory, accelerated candidate generation, and plans for further clinical catalysts as well as regulatory discussions to clarify the approval pathway. » More on de.investing.com

At the Bank of America SMID Cap Virtual Conference, Recursion emphasized that AI can only create competitive advantages in drug discovery when combined with more than 50 petabytes of proprietary biological data and rigorous clinical execution. The company highlighted REC-4881 in familial adenomatous polyposis, which reduced polyp burden by 43% after 12 weeks and showed a 53% response rate after treatment pauses, and pointed to capital-efficient partnerships with Roche and Sanofi. Recursion has $556 million in cash (runway into early 2028) and cites upcoming catalysts such as additional clinical data, FDA discussions, and updates on RBM39 and PI3K. » More on de.investing.com

Ark Genomic Revolution ETF holds over $50 million of Recursion Pharmaceuticals as the company leverages AI, robotics and computer vision to generate large-scale biological data. Recursion has seven drug candidates in clinical stages, with REC-4881 showing proof-of-concept and additional phase 1b/2 data expected in the first half of 2027. The company has partnerships with Bayer, Roche and a technical collaboration with Nvidia, but currently has no approved drugs and limited revenue. Recursion forecasts funding into early 2028, making it a high-risk, speculative investment contingent on successful commercialization of its AI-driven pipeline. » More on finance.yahoo.com